Concerto Biosciences
Biotechnology company developing microbiome-based therapeutics using its high-throughput screening platform to identify and engineer beneficial microbial communities for human health.
Website
https://www.concertobio.comLocation
Cambridge, Massachusetts, USA
Founded
2020
Investors
1
Categories
microbiome, therapeutics, biotech, synthetic-biology, drug-discovery
Notes
Concerto Biosciences is a biotechnology company developing next-generation microbiome therapeutics. The company uses high-throughput screening and synthetic biology approaches to identify and engineer beneficial microbial communities that can treat human diseases.
Founded by MIT researchers, Concerto's platform enables the systematic exploration of microbial interactions to discover therapeutic consortia with defined mechanisms of action.
Team
- Cheri Ackerman, Ph.D. - Co-founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/cheriackerman
- Jared Kehe, Ph.D. - Co-founder & Chief Technology Officer
- LinkedIn: linkedin.com/in/jaredkehe
Additional Research Findings
- Portfolio company of Corundum Systems Biology
- High-throughput microbiome screening platform
- Synthetic biology approach to microbiome therapeutics
- MIT spinout
- Focus on defined microbial consortia
- Mechanism-based therapeutic development
- Cambridge, Massachusetts headquarters
- Contact: [email protected]
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Corundum Systems Biology | Tokyo, Japan | biotech-focused | seedseries-a+1 | 9 |